3538 results

FDA approves US oriented clinical study of Bentley’s BeGraft and Cook’s Zenith® Fenestrated+ Endovascular Graft for treatment of aortic aneurysms CAUTION: Investigational device. Limited by United States law to investigational use.

28 Jun 2023

30 years of primary PCI – a tale of perseverance

16 May 2023

Over the last 30 years, primary PCI (pPCI) has evolved from an experimental ‘rescue’ intervention to an essential routine procedure – performed daily in cathlabs around the world – which is responsible for saving millions of lives. However, its path to success was far from smooth.

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!

17 Oct 2020

PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author

Hector Garcia

Percutaneous aspiration of vegetation to relieve obstruction in surgically repaired mitral valve

16 Jan 2025

This image highlights the challenges of managing infective endocarditis (IE) and explores the potential role of transcatheter extraction devices in addressing unmet needs for patients who cannot undergo surgery.

Comparison of noncompliant balloon with drug-coating balloon angioplasties for side branch after provisional stenting for patients with true coronary bifurcation lesions: The prospective, multicenter, randomized DCB-BIF Trial

03 Nov 2024

Aaysha Cader provides her take on the DCB-BIF Trial presented by Shao-Liang Chen at TCT 2024 in Washington.

Author

Aaysha Cader

Bentley buys key suppliers and engages employees in planned IPO

24 Apr 2023

3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications

22 Mar 2022

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Author

Ali Nazmi Calik

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Author

Nicola Ryan

Biocardia receives FDA breakthrough device designation for CardiAMP Cell Therapy System for heart failure

03 Feb 2022

Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES

30 Aug 2023

Alex Sticchi provides his take on the 3-year results of HOST-POLYTECH-ACS RCT which were presented by Hyo-Soo Kim during the ESC 2023 congress in Amsterdam.

Author

Alessandro Sticchi

The 2023 ESH Hypertension Guidelines revisit the role of renal denervation

05 Sep 2023

The 2023 European Society of Hypertension (ESH) guidelines were recently presented at the 32nd annual European Meeting on Hypertension and Cardiovascular Protection and simultaneously published in the Journal of Hypertension.1 While wide parts of the guidelines do not substantially differ from the previous 2018 European Society...

Author

Lucas Lauder

Author

Felix Mahfoud

Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial

29 Mar 2025

Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.

Author

Ali Nazmi Calik

Future directions of drug-coated balloon angioplasty

06 Feb 2025

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Author

Fernando Alfonso

Author

Javier Cuesta

Transfemoral TAVI in the horizontal aorta

12 May 2020

Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.

Implantation of the Portico With FlexNav TAVI System in a patient with aortic stenosis, severe renal impairment, and diffuse iliac atherosclerosis

12 May 2020

Real-world case report illustrating the benefits of the Portico with FlexNav TAVI system.

NOTION-3 - Percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation

01 Sep 2024

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

Author

Chiara De Biase

Author

Jacob Lønborg

Author

Ali Nazmi Calik

OPTION-STEMI: Immediate versus staged complete revascularisation during index admission in patients with STEMI and multivessel disease

02 Sep 2025

Mirvat Alasnag provides her take on OPTION-STEMI, presented by Youngkeun Ahn at ESC Congress 2025 in Madrid.

Author

Mirvat Alasnag

Evidence base: A description of the key, so far published, studies in the space of drug coated balloons

23 Jan 2025

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Author

Hector Garcia-Garcia

Author

Jorge Sanz-Sanchez